The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
|Articles|October 7, 2022
Exploring Recent Developments in the Treatment of Patients With Hormone Receptor– Positive Breast Cancer
A select group oncology experts met to engage in a virtual discussion workshop moderated by oncologist Erika Hamilton, MD. The overall objectives were to review recent data on therapeutic advances in HR+ BC. This article summarizes data from recent trials in early HR+ and TNBC; HR+ metastatic BC, focusing on use of CDK4/6 inhibitors in the first line and second line and beyond; and promising new endocrine therapies that may represent the future direction of HR+ cancer treatment.
Advertisement
Advertisement
Related to this article
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Five Under 5: Top Oncology Videos for the Week of 9/20
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5